2015, Volume 8, Issue 1, pp 24 – 27

Mesenchymal stem cells in multiple sclerosis – translation to clinical trials

SCImago Journal & Country Rank

Issues

Special Issues

Authors and Affiliations

Correspondence to:Adriana Dulamea, MD, PhD, “Fundeni” Clinical Institute 258 Fundeni Street, Bucharest, Romania Mobile phone: +40 723 258 672, Fax: +4021 318 04 20, E-mail: adrianadulamea@gmail.com

Abstract

Multiple sclerosis is a chronic inflammatory disease of the central nervous system, characterized by an aberrant activation of the immune system and combining demyelination with neurodegeneration. Studies on experimental models of multiple sclerosis revealed immunomodulatory and immunosuppressive properties of mesenchymal stem cells. Clinical trials using mesenchymal stem cells therapy in multiple sclerosis patients showed tolerability, safety on short term, some immunomodulatory properties reducing the Th1 proinflammatory response and the inflammatory MRI parameters. The author reviews the data about experimental studies and clinical trials using mesenchymal stem cells for the treatment of multiple sclerosis.

Abbreviations: MS = multiple sclerosis, RRMS = relapsing-remitting multiple sclerosis, PPMS = primary progressive multiple sclerosis, EAE = experimental autoimmune encephalomyelitis, MOG = myelin oligodendrocyte glycoprotein, PLP = proteolipid protein, MSCs = mesenchymal stem cells, CNS = central nervous system, IT = intrathecal, ALS = amyotrophic lateral sclerosis, MSC-NPs = mesenchymal stem cell-neural progenitors, EDSS = expanded disability status score.

Keywords

About this article

PMC ID: 4397514
PubMed ID: 25914733
DOI: 

Article Publishing Date (print): Jan-Mar 2015
Available Online: 

Journal information

ISSN Printing: 1844-122X
ISSN Online: 1844-3117
Journal Title: Journal of Medicine and Life

Copyright License: Open Access

This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.


SCImago Journal & Country Rank

Issues

Special Issues